Trial Profile
Study to evaluate the 123I-meta-iodobenzylguanidine (MIBG) Myocardial Scintigraphy as a marker of language function in newly diagnosed patients with Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Oct 2018
Price :
$35
*
At a glance
- Drugs Iobenguane (Primary)
- Indications Parkinson's disease
- Focus Diagnostic use
- 04 Oct 2018 New trial record